Bruce serves on UCB Pharma’s Scientific Advisory Board, Shire’s Scientific Advisory Board, and Pfizer’s Healthcare “R&D 2020? Innovation Think Tank, as well as several other advisory boards for academic medical centers. He also joined Science Exchange’s Reproducibility Initiative Advisory Board, focused on improving the reliability of translational research. Prior to joining Atlas in 2005, Bruce was an investor with Caxton Health Holdings and before that, a consultant at McKinsey & Company, where he helped to build the Pharma R&D practice. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Prior to Zalicus, Dr. Corrigan joined the specialty pharmaceutical company Sepracor Inc. in 2003 (now known as Sunovion Pharmaceuticals, Inc.) and served as their executive vice president of research and development until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, where he served most recently as Group Vice President of Global Clinical Research and Experimental Medicine.
Before Dr. Corrigan entered the pharmaceutical industry, he spent five years in academic research at the University of North Carolina, School of Medicine, focusing on psychoneuroendocrinology and maintains a faculty appointment as Adj. Prof. in the Psychiatry Dept. He is a Distinguished Fellow of the American Psychiatric Association.
Dr. Corrigan serves on the Board of Cardiome Pharma Corporation, Quartet Medicine, Synereca Pharmaceuticals and Pamlico Biopharma (both Acele Biopharma companies). He had served on the board of directors of Cubist Pharmaceuticals where he chaired the Scientific Committee and of Avanir Pharmaceuticals, Inc. where he also served as their chair of the SAC. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
Previously, David was a member of the Executive Team at Infinity Pharmaceuticals (Nasdaq: INFI) and was responsible for all clinical research activities as the head of clinical development and medical affairs, as well as co-chairing the company’s Scientific Leadership Team. In addition, as a member of the Executive Team, he shared responsibility for the creation and implementation of the overall corporate and business strategy that included going public in 2006, and establishing major corporate alliances with J&J, Amgen, Novartis, Medimmune/AZ and Purdue Pharma.
David obtained his MD from Harvard Medical School and completed his internship and residency training in internal medicine at Massachusetts General Hospital. Prior to his medical training, he was a curriculum director at Stanford University Medical Center, where he created Stanford’s first case-based medical ethics curriculum. He received a BA with honors from Stanford University. David serves on the board of Acera: The Massachusetts School for Science, Creativity, and Leadership, a STEM focused K-8 school, which he and his wife Courtney started in 2009.
Most recently, Elaine was a General Partner with the venture fund, EuclidSR Partners. There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept.
Prior to joining ESR, Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron. Previously, she served as Director of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D.
Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.